What we do Dr Reddy's Laboratories is a global pharmaceutical company offering APIs, generics, biosimilars, and innovative formulations across key therapeutic areas. |
Founded in 1,984 |
Market share Among India's leading pharma firms with significant presence in US, India, Russia, and Europe markets. |
Problem solved Provides affordable and innovative medicines to address healthcare needs globally, focusing on major therapeutic segments. |
Top clients or who we serve Serves B2B and B2C customers including healthcare providers, hospitals, and pharmaceutical companies worldwide. |
Key management - |
Our journey and innovations Founded in 1984, pioneered generic drug approvals, biosimilars, expanded globally through acquisitions, and launched novel vaccines and therapies. |
Where we operate Operates in over 83 countries including USA, India, Russia, Europe, and emerging markets. |
Top products or what we offer Offers APIs, generics, biosimilars, proprietary drugs, vaccines, and custom pharmaceutical services. |
Top brands Reductil, Cresp, Peg-grafeel, Hevaxin, Resof, Lenalidomide Capsules, Sorafenib, Timolol Gel. |
Raw materials needed Active pharmaceutical ingredients and chemical intermediates essential for drug manufacturing. |
Raw materials supplier Globally sourced from approved chemical suppliers and internal manufacturing facilities. |
Recurring vs cyclical contribution Revenue largely recurring from generics and proprietary products with cyclical elements from new drug launches and regulation. |
Our industry position Key market leader in generics and biosimilars with strong R&D pipeline and global market access. |
Financial highlights FY2024 revenue ₹32,644 Crores; profit ₹5,655 Crores; robust EBITDA margins; consistent growth in global markets. |
Geographical revenue split Revenue mainly from United States (₹14,935 Cr), India (₹5,583 Cr), Russia (₹2,596 Cr), Emerging markets and Europe. |
Order book - |
Whats driving growth Product innovation, biosimilars, expanding global footprint, strategic collaborations, and increasing demand in emerging markets. |
Our future plans Focus on biosimilars, vaccines, digital therapeutics, expanding CDMO services, and entering new healthcare segments. |
Our green promise Committed to science-based net zero targets by 2045 with awards in water security and climate action. |
Our people and values 26,000+ employees from 57 nationalities emphasizing innovation, diversity, and compliance. |
Key challenges ahead Regulatory scrutiny, pricing pressures, competitive generic markets, and geopolitical risks. |
Interesting facts First Indian company with 180-day exclusivity for generics in US; launched world’s first biosimilar MAb. |
Risks and strategy Manages risks via robust compliance, diversified portfolio, strategic acquisitions and focusing on quality and sustainability. |
